ENVB — Enveric Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Enveric Biosciences Says Regains Compliance With Nasdaq Bid Price Rule
Brief: Enveric Biosciences Launches Request-For-Proposals Solicitation Process For PsyAI Trademark
Brief: Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
Brief: Enveric Biosciences Announces Closing Of $5 Million Public Offering
Brief: Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
Brief: Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability
Brief: Enveric Biosciences Inc On Nov 20, Nasdaq Issued Delisting Notice On Failing To Meet Minimum Bid Price Requirement
Enveric Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Enveric Biosciences Signs Out-Licensing Agreement With MycoMedica Life Sciences For EB-002
Enveric Biosciences Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Enveric Biosciences Announces Positive Pharmacology And Safety Data For Lead Product, EB-003
Enveric Biosciences Inc reports results for the quarter ended in January - Earnings Summary
Enveric Biosciences Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Enveric Biosciences Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: Enveric Biosciences Advancing Pre-Clinical Development Of EB-003, Pre-Ind Meeting Targeted For Early 2025
Brief: Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics
Enveric Biosciences Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Enveric Biosciences Announces Signing Of Non-Binding Term Sheet With Undisclosed Licensee For Exclusive License To Patented Methods Of Treating Breast And Other Cancers Using Cannabinoids
Enveric Biosciences Inc reports results for the quarter ended in December - Earnings Summary